BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30420048)

  • 1. Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis.
    Sun W; Feng L; Yang X; Li L; Liu Y; Lv N; Lin D
    Hum Pathol; 2018 Nov; 81():261-271. PubMed ID: 30420048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.
    Sánchez-Font A; Chalela R; Martín-Ontiyuelo C; Albero-González R; Dalmases A; Longarón R; Alonso-Espinaco V; Curull V; Bellosillo B; Pijuan L
    Cancer Cytopathol; 2018 Oct; 126(10):860-871. PubMed ID: 30291816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of nonmucinous lepidic component with mild nuclear atypia in the discrimination of multiple primary lung cancers from intrapulmonary metastases.
    Sun W; Liu Y; Liu XY; Lin DM; Lv N
    Int J Clin Exp Pathol; 2014; 7(11):7583-96. PubMed ID: 25550795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
    Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer.
    Canepa M; Patel NR; Griffith RC; Ng TT; Azzoli CG
    J Thorac Oncol; 2019 Jul; 14(7):e153-e155. PubMed ID: 31235043
    [No Abstract]   [Full Text] [Related]  

  • 6. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
    Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.
    Takamochi K; Oh S; Matsuoka J; Suzuki K
    Lung Cancer; 2012 Mar; 75(3):313-20. PubMed ID: 22209037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological and molecular study for synchronous lung adenocarcinoma staging.
    Donfrancesco E; Yvorel V; Casteillo F; Stachowicz ML; Patoir A; Tiffet O; Péoc'h M; Forest F
    Virchows Arch; 2020 Jun; 476(6):835-842. PubMed ID: 31900636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases.
    Patel SB; Kadi W; Walts AE; Marchevsky AM; Pao A; Aguiluz A; Mudalige T; Liu Z; Deng N; Lopategui J
    J Mol Diagn; 2017 Nov; 19(6):870-880. PubMed ID: 28866070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma.
    Mackinnon AC; Luevano A; de Araujo LC; Rao N; Le M; Suster S
    Mod Pathol; 2014 Aug; 27(8):1063-72. PubMed ID: 24390215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesions in patients with multifocal adenocarcinoma are more frequently in the right upper lobes.
    Kaneda H; Uemura Y; Nakano T; Taniguchi Y; Saito T; Konobu T; Saito Y
    Interact Cardiovasc Thorac Surg; 2012 Oct; 15(4):627-32. PubMed ID: 22733594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
    Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
    Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
    Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
    BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
    Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
    Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
    Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.
    Simon E; Bick T; Sarji S; Shentzer T; Prinz E; Yehiam L; Sabo E; Ben-Izhak O; Hershkovitz D
    Oncotarget; 2017 Jul; 8(28):45736-45749. PubMed ID: 28501852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.